View Item 

Show simple item record

Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck

dc.contributor.authorDoroshow, Jamesen_US
dc.contributor.authorDallaire, Brianen_US
dc.contributor.authorCarlson, Randallen_US
dc.contributor.authorGyves, John W.en_US
dc.contributor.authorGrillo-Lopez, Antonioen_US
dc.contributor.authorRobert, Franciscoen_US
dc.contributor.authorAdams, Daviden_US
dc.contributor.authorVelez-Garcia, Enriqueen_US
dc.contributor.authorCripps, Christineen_US
dc.contributor.authorUrba, Susan G.en_US
dc.date.accessioned2006-09-11T18:22:57Z
dc.date.available2006-09-11T18:22:57Z
dc.date.issued1992-03en_US
dc.identifier.citationUrba, Susan; Doroshow, James; Cripps, Christine; Robert, Francisco; Velez-Garcia, Enrique; Dallaire, Brian; Adams, David; Carlson, Randall; Grillo-Lopez, Antonio; Gyves, John; (1992). "Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck." Cancer Chemotherapy and Pharmacology 31(2): 167-169. <http://hdl.handle.net/2027.42/46923>en_US
dc.identifier.issn0344-5704en_US
dc.identifier.issn1432-0843en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46923
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1451236&dopt=citationen_US
dc.description.abstractA total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m 2 . The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.en_US
dc.format.extent266540 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherOncologyen_US
dc.subject.otherCancer Researchen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.titleMulticenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and necken_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MI, USA; Department of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationotherSan Juan Veterans' Hospital, San Juan, PR, USA; University of Alabama at Birmingham, Birmingham, AL, USAen_US
dc.contributor.affiliationotherDepartment of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationotherCity of Hope National Medical Center, Duarte, CA, USAen_US
dc.contributor.affiliationotherOttawa Regional Cancer Center, Ottawa, Ontario, Canadaen_US
dc.contributor.affiliationotherUniversity of Puerto Rico School of Medicine, San Juan, Puerto Rico, USAen_US
dc.contributor.affiliationotherDepartment of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationotherDepartment of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationotherDepartment of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid1451236en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46923/1/280_2004_Article_BF00685106.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00685106en_US
dc.identifier.sourceCancer Chemotherapy and Pharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
280_2004_Article_BF00685106.pdf
Size:
260.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.